Why the study?
Is the risk of severe cardiovascular toxicity (thromboembolic events) underreported in patients with cervical cancer receiving concurrent irradiation and cisplatin chemotherapy?
Is the risk of severe cardiovascular toxicity (thromboembolic events) underreported in patients with cervical cancer receiving concurrent irradiation and cisplatin chemotherapy?
The risk of life-threatening thromboembolic events in cervical cancer patients receiving cisplatin and irradiation may be significantly underreported in prospective trials.
No takes yet. Share an insight, caveat, or question.
May indicate underreporting of severe cardiovascular toxicity with cisplatin-radiation in cervical cancer; challenges prospective trial consensus and needs validation.
Anders et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: